Paz-Ares's Lab
@PazAresLab
Research group @CNIOStopCancer and H12O led by @LuisPaz_Ares. Exploring new therapies for lung cancer. Tweets by @santi14borrego, Raquel López e Itziar Otano
ID:1445452821327847426
https://www.cnio.es/investigacion-e-innovacion/programas-cientificos/programa-de-investigacion-clini 05-10-2021 18:16:41
1,2K Tweets
958 Followers
658 Following
📷¡Reserva el 4 de mayo!
📷Darth Vader, sus tropas imperiales y #R2KT estarán en #Pamplona el próximo 4 de mayo y queremos que tú nos acompañes.
📷Asociación Española Contra el Cáncer Navarra y ThePinkForce Fundación han unido su Fuerza para ofrecerte el evento del año.
¡No te lo puedes perder!
17h. Plaza de Baluarte
Happy International Day of Immunology to all the dedicated researchers working tirelessly to advance our understanding of the immune system and develop life-saving vaccines and treatments! Your contributions are invaluable. #ImmunologyDay #ScienceHeroes 🧬💉🔬
A heterologous vaccine (adenovirus prime, samRNA boost) targeting 20 neoantigens from common KRAS and TP53 mutations was safe when combined with ICB in a phase I trial. bit.ly/4aPVFHT Gritstone bio
🔴📣 𝗨𝗡𝗜𝗗𝗔𝗗 𝗖𝗥𝗜𝗦 𝗗𝗘 𝗜𝗡𝗠𝗨𝗡𝗢-𝗢𝗡𝗖𝗢𝗟𝗢𝗚𝗜𝗔
➡️ Para el Dr. Luis Paz-Ares, entrega Dña. Inmaculada Ibáñez de Cáceres, directora general de Investigación y Docencia de la consejería de Sanidad de la Comunidad de #Madrid .
#DíaCienciaCRIS24
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity - check out this review from The Crick Julian Downward & Miriam Molina Arcas in Cancer Cell #AACR24 hubs.li/Q02rwVbs0
Find me now in AACR #AACR24 , section 35 board 17 presenting my poster on enabling biomarkers of chromosomal instability for tumor only targeted gene panel sequencing data using a novel computational tool. Tailor Bio CNIO Stop Cancer Geoff Macintyre UAI_imas12 Luis Paz-Ares
🔛Overcoming resistance to KRASG12C inhibitors #lungcancer
✅Come visit us AACR #AACR24
1930 Section 24, board 8
Alba Santos Irene Ferrer Sánchez CNIO Stop Cancer UAI_imas12 Complutense CIBERONC
Just published with the #AACR24 talk by Charles Swanton. Spatial Architecture of Myeloid & T Cells Orchestrates Immune Evasion & Clinical Outcome in #LungCancer .
bit.ly/3PQMZbZ
Katey Enfield Emma Colliver Claudia Lee Alastair Magness eriksahailab @___mihaela___ The Crick
Congratulations Dr. Nuñez-Buiza. Very proud of you, Ángel!! 💪🏼🍾🍾
Complutense UAI_imas12 CNIO Stop Cancer
🔔Yesterday and today we are happy to be celebrating the I retreat of the #Bioinformatics retreat of CIBERONC in wonderful #LaCristalera . Full house with representatives 🧑💻👩💻of all our #CancerResearch groups and plenty of #learning and #collaboration . 🔝🔝
🧬 Bridging #RNA Biology and Therapy: Exploring the frontiers of Advanced Medicine 🌍🔝
📅 When: 9-11 October 2024
📍 Where: Cima Universidad de Navarra
🔶Registration here ➡️ doctaforum-events.org/2024/rnasympos…
#ARN #InvestigaciónCientífica #BiologíaMolecular
Revach et al. showed that in ICB-treated patients with melanoma or NSCLC, CD8+ TIL expression of CD38, an ecto-enzyme involved in NAD+ catabolism, increased in parallel with co-inhibitory receptor and inversely with [...] bit.ly/4cDXCsd Or-Yam Revach Broad Institute Mass General Research Institute
![Revach et al. showed that in ICB-treated patients with melanoma or NSCLC, CD8+ TIL expression of CD38, an ecto-enzyme involved in NAD+ catabolism, increased in parallel with co-inhibitory receptor and inversely with [...] bit.ly/4cDXCsd @oryamush @broadinstitute @MGH_RI](https://pbs.twimg.com/media/GKVLnxAXsAAUlMt.jpg "ACIR (@ACIR_org) on Twitter photo 2024-04-04 15:30:22 Revach et al. showed that in ICB-treated patients with melanoma or NSCLC, CD8+ TIL expression of CD38, an ecto-enzyme involved in NAD+ catabolism, increased in parallel with co-inhibitory receptor and inversely with [...] bit.ly/4cDXCsd @oryamush @broadinstitute @MGH_RI")
To overcome ICB resistance in NSCLC, Lim, Salehi-Rad et al. evaluated intratumoral (IT) vaccination with CXCL9- and CXCL10-engineered dendritic cells (CXCL9/10-DC) in multiple murine models of syngeneic [...] bit.ly/4aFS0fq David Geffen School of Medicine at UCLA
![To overcome ICB resistance in NSCLC, Lim, Salehi-Rad et al. evaluated intratumoral (IT) vaccination with CXCL9- and CXCL10-engineered dendritic cells (CXCL9/10-DC) in multiple murine models of syngeneic [...] bit.ly/4aFS0fq @dgsomucla](https://pbs.twimg.com/media/GKUbjOxWkAA1tdU.jpg "ACIR (@ACIR_org) on Twitter photo 2024-04-04 12:00:20 To overcome ICB resistance in NSCLC, Lim, Salehi-Rad et al. evaluated intratumoral (IT) vaccination with CXCL9- and CXCL10-engineered dendritic cells (CXCL9/10-DC) in multiple murine models of syngeneic [...] bit.ly/4aFS0fq @dgsomucla")
A 2022 Review by Egle Kvedaraite and @realFlorentGinhoux contextualizes over five decades of research on #DendriticCells and their roles in #cancer .
Catch up on the work: scim.ag/6q8 #WeekendReads
Franken and Bila et al. demonstrated that single-dose neoadjuvant anti-PD-L1 immunotherapy in patients with HNSCC led to intratumoral expansion of CD8+ Tem, Trm, and Tex cells, and the addition of [...] bit.ly/49ZkiBn Amelie Franken CCB_VIB_KUL @DiLa_lab
![Franken and Bila et al. demonstrated that single-dose neoadjuvant anti-PD-L1 immunotherapy in patients with HNSCC led to intratumoral expansion of CD8+ Tem, Trm, and Tex cells, and the addition of [...] bit.ly/49ZkiBn @AmelieFranken @vib_ccb @LambrechtsDlab](https://pbs.twimg.com/media/GJNIviWW8AAhnNq.jpg "ACIR (@ACIR_org) on Twitter photo 2024-03-21 15:45:08 Franken and Bila et al. demonstrated that single-dose neoadjuvant anti-PD-L1 immunotherapy in patients with HNSCC led to intratumoral expansion of CD8+ Tem, Trm, and Tex cells, and the addition of [...] bit.ly/49ZkiBn @AmelieFranken @vib_ccb @LambrechtsDlab")
